Filing Flows › 8-K events › Seres Therapeutics
Seres Therapeutics: departure or appointment of directors and officers
Form 8-K filed Oct 26, 2026 · items 5.02
What the filing says
On October 22, 2026, Marella Thorell, Executive Vice President and Chief Financial Officer of Seres Therapeutics, Inc. (the “Company”), resigned from her positions as Executive Vice President and Chief Financial Officer of the Company, effective November 15, 2026 (the “Effective Date”). Following the Effective Date, Ms
Read the filing on SEC EDGAR →
What usually followsAcross 39,174 8-Ks reporting Item 5.02 (directors and officers: departures, appointments, pay) in our universe, the stock's median move the next session was −0.1% (typical size ±1.4%, up 48% of the time); over the following 21 sessions, +0.7%. Every item ranked →
What this kind of filing means
Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.
Seres Therapeutics at a glance
Seres Therapeutics, Q3 2026: revenue $593K (+69% year over year). The chart follows the revenue to costs, profit and cash.
Seres Therapeutics: every quarter, Q/Q and Y/Y, holders and guidance →
Seres Therapeutics’s other material 8-Ks
- Nov 4, 2026 — FDA decisions SERES THERAPEUTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND ANNOUNCES PLANS FOR ADVANCING DE
Other recent cfo changes
- Karbon-X Nov 6, 2026
- Power Solutions International Nov 6, 2026
- Audax Private Credit Fund, LLC Nov 6, 2026
- Audax Credit BDC Nov 6, 2026
- Blaize Holdings Nov 5, 2026
- Valion Bio Nov 5, 2026
- Digital Turbine Nov 5, 2026
- TransUnion Nov 5, 2026
- Teads Holding Nov 5, 2026
- Novelis Nov 5, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.